[1] Marcocci C, Cetani F, Rubin MR, et al. Parathyroid carcinoma [J]. J Bone Miner Res, 2008, 23(12): 1869-1880.
[2] Sharretts JM, Kebebew E, Simonds WF. Parathyroid cancer[J]. Semin Oncol, 2010, 37(6): 580-590.
[3] Guarnieri V, Battista C, Muscarella LA, et al. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort [J]. Cell Oncol (Dordr), 2012, 35(6): 411-422.
[4] Sidhu PS, Talat N, Patel P, et al. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm [J]. Eur Radiol, 2011, 21(9): 1865-1873.
[5] Elliott KL, Catimel B, Church NL, et al. Immunopurification of adenomatous polyposis coli (APC) proteins [J]. BMC Res Notes, 2013 (6): 429.
[6] Kim JH, Kim YH, Song GY, et al. Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of beta-catenin degradation [J]. Food Chem Toxicol, 2014(67): 87-95.
[7] Wang L, Liu X, Gusev E, et al. Regulation of the phosphorylation and nuclear import and export of beta-catenin by APC and its cancer-related truncated form [J]. J Cell Sci, 2014, 127(8): 1647-1659.
[8] Juhlin CC, Nilsson IL, Johansson K, et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas [J]. Endocr Pathol, 2010, 21(3): 166-177.
[9] Svedlund J, Auren M, Sundstrom M, et al. Aberrant WNT/beta-catenin signaling in parathyroid carcinoma [J]. Mol Cancer, 2010(9): 294.
[10] Tominaga Y, Tsuzuki T, Matsuoka S, et al. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease [J]. World J Surg, 2008, 32(5): 815-821.
[11] Agarwal SK, Simonds WF, Marx SJ. The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3 [J]. Mol Cancer, 2008(7): 65.
[12] Wang O, Wang C, Nie M, et al. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas [J]. PLoS One, 2012, 7(9): e45567.
[13] Rather MI, Swamy S, Gopinath KS, et al. Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics [J]. J Biol Chem, 2014, 289(2): 968-976.
[14] Newey PJ, Bowl MR, Thakker RV. Parafibromin-functional insights [J]. J Intern Med, 2009, 266(1): 84-98.
[15] Moon S, Kim JH, Shim JY, et al. Analysis of aberrantly spliced HRPT2 transcripts and the resulting proteins in HPT-JT syndrome [J]. Mol Genet Metab, 2010, 100(4): 365-371.
[16] Rozenblatt-Rosen O, Nagaike T, Francis JM, et al. The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors [J]. Proc Natl Acad Sci USA, 2009, 106(3): 755-760.
[17] Hahn MA, Dickson KA, Jackson S, et al. The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination [J]. Hum Mol Genet, 2012, 21(3): 559-568.
[18] Rather MI, Nagashri MN, Swamy SS, et al. Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics [J]. J Biol Chem, 2013, 288(1): 608-618.
[19] Zheng HC, Takahashi H, Li XH, et al. Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas [J]. Virchows Arch, 2008, 452(2): 147-155.
[20] Zheng HC, Wei ZL, Xu XY, et al. Parafibromin expression is an independent prognostic factor for colorectal carcinomas [J]. Hum Pathol, 2011, 42(8): 1089-1102.
[21] Newey PJ, Bowl MR, Cranston T, et al. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors [J]. Hum Mutat, 2010, 31(3): 295-307.
[22] Gurung B, Feng Z, Iwamoto DV, et al. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome [J]. Cancer Res, 2013, 73(8): 2650-2658.
[23] Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling [J]. Trends Biochem Sci, 2013, 38(8): 394-402.
[24] Kuwahara M, Suzuki J, Tofukuji S, et al. The Menin-Bach2 axis is critical for regulating CD4 T-cell senescence and cytokine homeostasis [J]. Nat Commun, 2014(5): 3555.
[25] Tsukada T, Nagamura Y, Ohkura N. MEN1 gene and its mutations: basic and clinical implications [J]. Cancer Sci, 2009, 100(2): 209-215.
[26] Francis J, Lin W, Rozenblatt-Rosen O, et al. The menin tumor suppressor protein is phosphorylated in response to DNA damage [J]. PLoS One, 2011, 6(1): e16119.
[27] Tharmalingam S, Daulat AM, Antflick JE, et al. Calcium-sensing receptor modulates cell adhesion and migration via integrins [J]. J Biol Chem, 2011, 286(47): 40922-40933.
[28] Singh N, Promkan M, Liu G, et al. Role of calcium sensing receptor (CaSR) in tumorigenesis [J]. Best Pract Res Clin Endocrinol Metab, 2013, 27(3): 455-463.
[29] Brennan SC, Thiem U, Roth S, et al. Calcium sensing receptor signalling in physiology and cancer [J]. Biochim Biophys Acta, 2013, 1833(7): 1732-1744.
[30] Manning AT, O'Brien N, Kerin MJ. Roles for the calcium sensing receptor in primary and metastatic cancer [J]. Eur J Surg Oncol, 2006, 32(7): 693-697.
[31] Yan J, Brown TR. Cell proliferation and expression of cell cycle regulatory proteins that control the G1/S transition are age dependent and lobe specific in the Brown Norway rat model of prostatic hyperplasia [J]. Endocrinology, 2008, 149(1): 193-207.
[32] Tamura G, Miyoshi H, Ogata SY, et al. Parathyroid carcinoma with anaplastic feature: association of a p53 gene mutation with anaplastic transformation [J]. Pathol Int, 2009, 59(2): 107-110. |
